I look forward to seeing this paper published. I listened to an interview with Prof Bergquist and he said something interesting: they are not only trying to find out if LDN and Mestinon work for some patients, but also why.
I think that’s exactly what we need, seeing that there are such contradicting reports about their efficacy. Why do some patients get benefits, while others don’t?
I have not tested Mestinon, but I am on LDN since last year. The benefits are not life-changing, but they are there. Less muscle pain. Less fluey feeling. Shorter PEM. Less ”I’m dying/I’m poisoned” feeling. I still have all of these symptoms, and I am still severe and bedbound 95% of the time, but when you are as sick as I am, even 1% alleviation of suffering is something.
I took a break after 6 months on LDN to see if there was any difference and I did feel slightly worse, so I started it again after a month. I am on a low dose, I can only tolerate 1,5 mg. Anything higher and I get really scary side effects.